Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Lilly Asia Ventures

Investor type Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 168
Average round size
The average size of a deal this fund participated in
Portfolio companies 99
Rounds per year 12.00
Lead investments 30
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 27
Key employees 4
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Medical
  • Biopharma

In 2008 was created Lilly Asia Ventures, which is appeared as VC. The main office of represented VC is situated in the Shanghai. The venture was found in Asia in China.

The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Lilly Asia Ventures, startups are often financed by OrbiMed, ARCH Venture Partners, Qiming Venture Partners. The meaningful sponsors for the fund in investment in the same round are ARCH Venture Partners, Vivo Capital, Temasek Holdings. In the next rounds fund is usually obtained by Hillhouse Capital Group, Qiming Venture Partners, Temasek Holdings.

The overall number of key employees were 4.

We can highlight the next thriving fund investment areas, such as Biotechnology, Health Care. For fund there is no match between the location of its establishment and the land of its numerous investments - United States. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Innovent Biologics, Alector, Betta Pharmaceuticals. The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager.

The high activity for fund was in 2018. The usual things for fund are deals in the range of 50 - 100 millions dollars. Opposing the other organizations, this Lilly Asia Ventures works on 15 percentage points less the average amount of lead investments. The increased amount of exits for fund were in 2019. The fund is constantly included in 2-6 investment rounds annually. The real fund results show that this VC is 16 percentage points more often commits exit comparing to other companies. The average startup value when the investment from Lilly Asia Ventures is 500 millions - 1 billion dollars.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Lilly Asia Ventures:
Typical Co-investors
Lilly Asia Ventures is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Lilly Asia Ventures:

Funds with similar focus

Funds from China
Funds with similar focus located in China:
Funds with the same geo focus
Funds with similar geography of portfolio companies:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Pulnovo Medical

Medical Device
11 Nov 2022 Wuxi, Anhui, China

Neukio Biotherapeutics

$50M02 Sep 2022 Shanghai, Shanghai, China

Fountain Medical Development

Health Care
$150M04 Jul 2022 New York, New York, United States


$70M02 Jun 2022 Suzhou, Jiangsu, China

Rona Therapeutics

Health Care
$33M07 Apr 2022 Shanghai, Shanghai, China

IMPACT Therapeutics

14 Mar 2022 Xuanwu District, Jiangsu, China

GluBio Pharmaceutical

Health Care
$50M28 Feb 2022 Hangzhou, Zhejiang, China

ArriVent Biopharma

$69M15 Feb 2022 Pennsylvania Furnace, Pennsylvania, United States

Pilot Biotechnology

Health Care
$15M08 Feb 2022 Suzhou, Jiangsu, China
ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform

– ShouTi Inc. announced the close of a $100m Series B financing round.
– The round was led by BVF Partners. Additional new investors include Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Lilly Asia Ventures, Monashee Capital, Sage Partners, Stork Capital, Surveyor Capital (a Citadel company), TCG X, Terra Magnum Capital Partners, Woodline Partners, and co-founder and strategic partner Schrödinger.
– Existing investors also participated in the financing, including Eight Roads, F-Prime Capital Partners, Qiming Venture Partners, Sequoia Capital China, TF Capital and Wuxi AppTec.

ADARx Raises $75 Million to Advance Growing Pipeline

– ADARx Pharmaceuticals, Inc. completed a $75m Series B financing.
– The round was co-led by SR One Capital Management and OrbiMed Advisors.
Sirona Capital joined this financing as well as existing investor Lilly Asia Ventures.
– The proceeds from the Series B financing will be used to advance ADARx’s proprietary RNA platform technologies for base editing, inhibition, degradation, and delivery.
– The proceeds will also be used to transition ADARx’s growing pipeline of research phase products into the clinic including initiation of a Phase 1 clinical trial for ADARx’s lead program.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Lilly Asia Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: